OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) has announced that India Ratings & Research (Ind-Ra) has affirmed a credit rating of [IND A-/Positive] for the company's additional bank loan facilities. This rating is consistent with the previous rating issued on June 03, 2025. The company has provided a copy of the press release from India Ratings and Research as an annexure to this intimation. This announcement is made pursuant to Regulation 30 read with Part A, Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
